This article is more than 5 years old. Information may no longer be current.

No advantage for low-molecular weight heparin in reducing postop inflammation in pediatric cataracts

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Despite previous suggestion to the contrary, the addition of low-molecular weight heparin to balanced salt solution during pediatric cataract surgery does not influence postoperative inflammation.

In a study, 20 patients were randomly assigned to receive balanced salt solution infused with enoxaparin, and 20 patients received no treatment. An AcrySof IOL (Alcon) was implanted in all patient eyes.

"At 1 month and 3 months, we did not find any inflammatory cells in any eyes in either group," Viraj A. Vasavada, MS, said at the American Society of Cataract and Refractive Surgery meeting here.

At 1 month, all eyes in the enoxaparin group and 57.1% of eyes in the non-treatment group had small cell deposits; 20% of eyes in the treatment group and none in the non-treatment group had posterior synechiae.

This was the first prospective, masked, randomized, controlled clinical trial looking at the effect of low-molecular weight heparin on inflammation in pediatric cataract, Ms. Vasavada said. A research grant for the study was provided by the ASCRS Foundation and the Howard Lieberman, MD, Foundation.